IDIBAPS, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Factor d'impacte: mitjana: 5.86, total: 228.61

Articles de l'any 2008

Original

• Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia

  Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S, Reina O, Ardanaz MT, Jares P, Garcia-Orad A, Pujana MA, Montserrat E, DeSanjose S, Campo E
  CANCER RES . 2008; 68: 10178-10186. IF: 7.672

• BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells

  Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D
  LEUKEMIA. 2008; 22: 1712-1720. IF: 6.924

• Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators

  Roue G, Pichereau V, Lincet H, Colomer D, Sola B
  ONCOGENE. 2008; 27: 4909-4920. IF: 6.44

• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication

  Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones J, Gonzalez-Barca E, Abella E, Gardella S, Escoda L, Perez-Ceballos E, Asensi A, Sayas MJ, Font L, Altes A, Muntanola A, Bertazzoni P, Rozman M, Aymerich M, Gine E, Montserrat E
  CLIN CANCER RES. 2008; 14: 155-161. IF: 6.25

• Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

  Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P, Villamor N, Montserrat E, Campo E, Colomer D
  CLIN CANCER RES . 2008; 14: 6907-6915. IF: 6.25

• Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival

  Marin-Aguilera M, Mengual L, Burset M, Oliver A, Ars E, Ribal MJ, Colomer D, Mellado B, Villavicencio H, Algaba F, Alcaraz A
  EUR UROL. 2008; 54: 1363-1372. IF: 5.634

• Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells

  Lopez-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M
  HAEMATOL-HEMATOL J. 2008; 93: 1843-1851. IF: 5.516

• High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

  Montoto S, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altes A, Besalduch J, Pedro C, Gardelia S, Escoda L, Asensio A, Vivancos P, Galan P, DeSevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, Lopez-Guillermo A
  HAEMATOL-HEMATOL J. 2008; 93: 207-214. IF: 5.516

• Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment

  Gine E, Crespo M, Muntanola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F
  HAEMATOL-HEMATOL J. 2008; 93: 75-82. IF: 5.516

• Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia

  Fernandez V, Jares P, Salaverria I, Gine E, Bea S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E
  HAEMATOL-HEMATOL J. 2008; 93: 132-136. IF: 5.516

• Central nervous system involvement in mantle cell lymphoma

  Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, Mercadal S, Campo E, Rozman C, Lopez-Guillermo A, Montserrat E
  ANN ONCOL. 2008; 19: 135-141. IF: 4.875

• Multiple Recurrent Chromosomal Breakpoints in Mantle Cell Lymphoma Revealed by a Combination of Molecular Cytogenetic Techniques

  Salaverria I, Espinet B, Carrio A, Costa D, Astier L, Slotta-Huspenina J, Quintanilla-Martinez L, Fend F, Sole F, Colomer D, Serrano S, Miro R, Bea S, Campo E
  GENE CHROMOSOME CANC. 2008; 47: 1086-1097. IF: 4.532

• Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis

  Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F
  ANN HEMATOL. 2008; 87: 269-276. IF: 2.342

• Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents

  Cibeira MT, Rozman M, Segarra M, Lozano E, Rosinol L, Cid MC, Filella X, Blade J
  CYTOKINE. 2008; 41: 244-253. IF: 2.169

• Primary cutaneous small/medium CD4(+) T-cell lymphomas: A heterogeneous group of tumors with different clinicopathologic features and outcome

  Garcia-Herrera A, Colomo L, Camos M, Carreras J, Balague O, Martinez A, Lopez-Guillermo A, Estrach T, Campo E
  J CLIN ONCOL. 2008; 26: 3364-3371. IF: 15.484

• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

  Sanz MA, Montesinos P, Vellenga E, Rayon C, DeLaSerna J, Parody R, Bergua JM, Leon A, Negri S, Gonzalez M, Rivas C, Esteve J, Milone G, Gonzalez JD, Amutio E, Brunet S, Garcia-Larana J, Colomer D, Calasanz MJ, Chillon C, Barragan E, Bolufer P, Lowenberg B
  BLOOD. 2008; 112: 3130-3134. IF: 10.896

• Hemoglobinopathy Newcastle: use of chromatography and first case reported in Spain

  Pereira MDM, Sibina MTC, Mateos EG, Corrons JLV
  MED CLIN-BARCELONA. 2008; 130: 455-458. IF: 1.337

• Comparison of evaluation procedures used by European external quality assessment scheme organizers for haemoglobin concentration and leukocyte concentration

  VanBlerk M, Albarede S, Deom A, Gutierrez G, Heller S, Nazor A, Pakkanen A, Rej R, Curran KM, Sarkany E, Skitek M, Vives-Corrons JL, Zaikin E, Libeer JC
  ACCREDIT QUAL ASSUR. 2008; 13: 145-148. IF: 0.717

Editorials

• Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years ago

  Grau JJ, Estrach T
  BREAST CANCER RES TR . 2008; 111: 11-13. IF: 4.453